Is Spotify a Millionaire-Maker Stock?
Spotify (NYSE:SPOT) may seem like an expensive proposition trading closer…
Sell
36
NMTC Quote, Financials, Valuation and Earnings
Last price:
$0.63
Seasonality move
:
-9.52%
Day range:
$0.61 - $0.65
52-week range:
$0.40 - $1.39
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.05x
P/B ratio:
6.47x
Volume:
146K
Avg. volume:
413.4K
1-year change:
-46.97%
Market cap:
$19M
Revenue:
$3.5M
EPS (TTM):
-$0.26
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
NMTC
NeuroOne Medical Technologies
|
$1.3M | -- | 157.41% | -57.14% | $1.45 |
|
IVF
INVO Fertility
|
$1.6M | -- | -8.8% | -- | -- |
|
NTRB
Nutriband
|
$665K | -$0.13 | 59.2% | -38.1% | $13.00 |
|
NVNO
enVVeno Medical
|
-- | -$0.34 | -- | -9.68% | $12.50 |
|
SINT
SINTX Technologies
|
$725K | -$0.71 | 20.07% | -96.14% | $30.00 |
|
XAIR
Beyond Air
|
$1.4M | -- | 195.4% | -- | $2.25 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
NMTC
NeuroOne Medical Technologies
|
$0.62 | $1.45 | $19M | -- | $0.00 | 0% | 3.05x |
|
IVF
INVO Fertility
|
$2.09 | -- | $2.2M | -- | $0.00 | 0% | 0.11x |
|
NTRB
Nutriband
|
$5.72 | $13.00 | $63.8M | -- | $0.00 | 0% | 28.36x |
|
NVNO
enVVeno Medical
|
$3.65 | $12.50 | $64M | -- | $0.00 | 0% | 356.07x |
|
SINT
SINTX Technologies
|
$2.59 | $30.00 | $6.5M | -- | $0.00 | 0% | 1.62x |
|
XAIR
Beyond Air
|
$0.20 | $2.25 | $17.3M | -- | $0.00 | 0% | 3.54x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
NMTC
NeuroOne Medical Technologies
|
-- | -0.602 | -- | 2.23x |
|
IVF
INVO Fertility
|
-- | 3.433 | -- | -- |
|
NTRB
Nutriband
|
1.68% | 3.138 | 0.28% | 4.65x |
|
NVNO
enVVeno Medical
|
-- | 0.246 | -- | -- |
|
SINT
SINTX Technologies
|
0.82% | 0.321 | 0.68% | 1.91x |
|
XAIR
Beyond Air
|
0.34% | -0.284 | 0.22% | 2.15x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
NMTC
NeuroOne Medical Technologies
|
$1.9M | $1.7M | -238.93% | -238.93% | 64.45% | $183.6K |
|
IVF
INVO Fertility
|
-- | -- | -- | -- | -- | -- |
|
NTRB
Nutriband
|
$191K | -$1.4M | -65.19% | -69.58% | -210.38% | -$1.1M |
|
NVNO
enVVeno Medical
|
-- | -$5M | -- | -- | -- | -$4M |
|
SINT
SINTX Technologies
|
$38K | -$1.6M | -146.19% | -148.9% | -875.52% | -$1.3M |
|
XAIR
Beyond Air
|
-$215K | -$11M | -151.32% | -225.36% | -1192.54% | -$8.3M |
NeuroOne Medical Technologies vs. Competitors
-
Which has Higher Returns NMTC or IVF?
INVO Fertility has a net margin of 54.53% compared to NeuroOne Medical Technologies's net margin of --. NeuroOne Medical Technologies's return on equity of -238.93% beat INVO Fertility's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital NMTCNeuroOne Medical Technologies58.85% $0.06 $2.9M IVFINVO Fertility-- -- -- -
What do Analysts Say About NMTC or IVF?
NeuroOne Medical Technologies has a consensus price target of $1.45, signalling upside risk potential of 135.7%. On the other hand INVO Fertility has an analysts' consensus of -- which suggests that it could grow by 187.08%. Given that INVO Fertility has higher upside potential than NeuroOne Medical Technologies, analysts believe INVO Fertility is more attractive than NeuroOne Medical Technologies.
Company Buy Ratings Hold Ratings Sell Ratings NMTCNeuroOne Medical Technologies1 0 0 IVFINVO Fertility0 0 0 -
Is NMTC or IVF More Risky?
NeuroOne Medical Technologies has a beta of 0.653, which suggesting that the stock is 34.671% less volatile than S&P 500. In comparison INVO Fertility has a beta of 2.243, suggesting its more volatile than the S&P 500 by 124.267%.
-
Which is a Better Dividend Stock NMTC or IVF?
NeuroOne Medical Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. INVO Fertility offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeuroOne Medical Technologies pays -- of its earnings as a dividend. INVO Fertility pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NMTC or IVF?
NeuroOne Medical Technologies quarterly revenues are $3.3M, which are larger than INVO Fertility quarterly revenues of --. NeuroOne Medical Technologies's net income of $1.8M is higher than INVO Fertility's net income of --. Notably, NeuroOne Medical Technologies's price-to-earnings ratio is -- while INVO Fertility's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeuroOne Medical Technologies is 3.05x versus 0.11x for INVO Fertility. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NMTCNeuroOne Medical Technologies3.05x -- $3.3M $1.8M IVFINVO Fertility0.11x -- -- --
-
Which has Higher Returns NMTC or NTRB?
Nutriband has a net margin of 54.53% compared to NeuroOne Medical Technologies's net margin of -211%. NeuroOne Medical Technologies's return on equity of -238.93% beat Nutriband's return on equity of -69.58%.
Company Gross Margin Earnings Per Share Invested Capital NMTCNeuroOne Medical Technologies58.85% $0.06 $2.9M NTRBNutriband29.58% -$0.12 $11.4M -
What do Analysts Say About NMTC or NTRB?
NeuroOne Medical Technologies has a consensus price target of $1.45, signalling upside risk potential of 135.7%. On the other hand Nutriband has an analysts' consensus of $13.00 which suggests that it could grow by 127.27%. Given that NeuroOne Medical Technologies has higher upside potential than Nutriband, analysts believe NeuroOne Medical Technologies is more attractive than Nutriband.
Company Buy Ratings Hold Ratings Sell Ratings NMTCNeuroOne Medical Technologies1 0 0 NTRBNutriband1 0 0 -
Is NMTC or NTRB More Risky?
NeuroOne Medical Technologies has a beta of 0.653, which suggesting that the stock is 34.671% less volatile than S&P 500. In comparison Nutriband has a beta of 1.185, suggesting its more volatile than the S&P 500 by 18.545%.
-
Which is a Better Dividend Stock NMTC or NTRB?
NeuroOne Medical Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nutriband offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeuroOne Medical Technologies pays -- of its earnings as a dividend. Nutriband pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NMTC or NTRB?
NeuroOne Medical Technologies quarterly revenues are $3.3M, which are larger than Nutriband quarterly revenues of $645.8K. NeuroOne Medical Technologies's net income of $1.8M is higher than Nutriband's net income of -$1.4M. Notably, NeuroOne Medical Technologies's price-to-earnings ratio is -- while Nutriband's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeuroOne Medical Technologies is 3.05x versus 28.36x for Nutriband. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NMTCNeuroOne Medical Technologies3.05x -- $3.3M $1.8M NTRBNutriband28.36x -- $645.8K -$1.4M
-
Which has Higher Returns NMTC or NVNO?
enVVeno Medical has a net margin of 54.53% compared to NeuroOne Medical Technologies's net margin of --. NeuroOne Medical Technologies's return on equity of -238.93% beat enVVeno Medical's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital NMTCNeuroOne Medical Technologies58.85% $0.06 $2.9M NVNOenVVeno Medical-- -$0.22 -- -
What do Analysts Say About NMTC or NVNO?
NeuroOne Medical Technologies has a consensus price target of $1.45, signalling upside risk potential of 135.7%. On the other hand enVVeno Medical has an analysts' consensus of $12.50 which suggests that it could grow by 242.47%. Given that enVVeno Medical has higher upside potential than NeuroOne Medical Technologies, analysts believe enVVeno Medical is more attractive than NeuroOne Medical Technologies.
Company Buy Ratings Hold Ratings Sell Ratings NMTCNeuroOne Medical Technologies1 0 0 NVNOenVVeno Medical1 0 0 -
Is NMTC or NVNO More Risky?
NeuroOne Medical Technologies has a beta of 0.653, which suggesting that the stock is 34.671% less volatile than S&P 500. In comparison enVVeno Medical has a beta of 0.803, suggesting its less volatile than the S&P 500 by 19.726%.
-
Which is a Better Dividend Stock NMTC or NVNO?
NeuroOne Medical Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. enVVeno Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeuroOne Medical Technologies pays -- of its earnings as a dividend. enVVeno Medical pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NMTC or NVNO?
NeuroOne Medical Technologies quarterly revenues are $3.3M, which are larger than enVVeno Medical quarterly revenues of --. NeuroOne Medical Technologies's net income of $1.8M is higher than enVVeno Medical's net income of -$4.5M. Notably, NeuroOne Medical Technologies's price-to-earnings ratio is -- while enVVeno Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeuroOne Medical Technologies is 3.05x versus 356.07x for enVVeno Medical. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NMTCNeuroOne Medical Technologies3.05x -- $3.3M $1.8M NVNOenVVeno Medical356.07x -- -- -$4.5M
-
Which has Higher Returns NMTC or SINT?
SINTX Technologies has a net margin of 54.53% compared to NeuroOne Medical Technologies's net margin of -882.81%. NeuroOne Medical Technologies's return on equity of -238.93% beat SINTX Technologies's return on equity of -148.9%.
Company Gross Margin Earnings Per Share Invested Capital NMTCNeuroOne Medical Technologies58.85% $0.06 $2.9M SINTSINTX Technologies19.79% -$1.26 $3.9M -
What do Analysts Say About NMTC or SINT?
NeuroOne Medical Technologies has a consensus price target of $1.45, signalling upside risk potential of 135.7%. On the other hand SINTX Technologies has an analysts' consensus of $30.00 which suggests that it could grow by 1058.3%. Given that SINTX Technologies has higher upside potential than NeuroOne Medical Technologies, analysts believe SINTX Technologies is more attractive than NeuroOne Medical Technologies.
Company Buy Ratings Hold Ratings Sell Ratings NMTCNeuroOne Medical Technologies1 0 0 SINTSINTX Technologies1 1 0 -
Is NMTC or SINT More Risky?
NeuroOne Medical Technologies has a beta of 0.653, which suggesting that the stock is 34.671% less volatile than S&P 500. In comparison SINTX Technologies has a beta of 0.821, suggesting its less volatile than the S&P 500 by 17.937%.
-
Which is a Better Dividend Stock NMTC or SINT?
NeuroOne Medical Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SINTX Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeuroOne Medical Technologies pays -- of its earnings as a dividend. SINTX Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NMTC or SINT?
NeuroOne Medical Technologies quarterly revenues are $3.3M, which are larger than SINTX Technologies quarterly revenues of $192K. NeuroOne Medical Technologies's net income of $1.8M is higher than SINTX Technologies's net income of -$1.7M. Notably, NeuroOne Medical Technologies's price-to-earnings ratio is -- while SINTX Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeuroOne Medical Technologies is 3.05x versus 1.62x for SINTX Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NMTCNeuroOne Medical Technologies3.05x -- $3.3M $1.8M SINTSINTX Technologies1.62x -- $192K -$1.7M
-
Which has Higher Returns NMTC or XAIR?
Beyond Air has a net margin of 54.53% compared to NeuroOne Medical Technologies's net margin of -1215.67%. NeuroOne Medical Technologies's return on equity of -238.93% beat Beyond Air's return on equity of -225.36%.
Company Gross Margin Earnings Per Share Invested Capital NMTCNeuroOne Medical Technologies58.85% $0.06 $2.9M XAIRBeyond Air-20.06% -$0.15 $18.4M -
What do Analysts Say About NMTC or XAIR?
NeuroOne Medical Technologies has a consensus price target of $1.45, signalling upside risk potential of 135.7%. On the other hand Beyond Air has an analysts' consensus of $2.25 which suggests that it could grow by 1047.37%. Given that Beyond Air has higher upside potential than NeuroOne Medical Technologies, analysts believe Beyond Air is more attractive than NeuroOne Medical Technologies.
Company Buy Ratings Hold Ratings Sell Ratings NMTCNeuroOne Medical Technologies1 0 0 XAIRBeyond Air1 1 0 -
Is NMTC or XAIR More Risky?
NeuroOne Medical Technologies has a beta of 0.653, which suggesting that the stock is 34.671% less volatile than S&P 500. In comparison Beyond Air has a beta of 0.250, suggesting its less volatile than the S&P 500 by 75.019%.
-
Which is a Better Dividend Stock NMTC or XAIR?
NeuroOne Medical Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Beyond Air offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeuroOne Medical Technologies pays -- of its earnings as a dividend. Beyond Air pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NMTC or XAIR?
NeuroOne Medical Technologies quarterly revenues are $3.3M, which are larger than Beyond Air quarterly revenues of $1.1M. NeuroOne Medical Technologies's net income of $1.8M is higher than Beyond Air's net income of -$13M. Notably, NeuroOne Medical Technologies's price-to-earnings ratio is -- while Beyond Air's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeuroOne Medical Technologies is 3.05x versus 3.54x for Beyond Air. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NMTCNeuroOne Medical Technologies3.05x -- $3.3M $1.8M XAIRBeyond Air3.54x -- $1.1M -$13M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
What Is a Millionaire-Maker Stock?
From time to time, investors will run across the term…
5 Investors to Follow Other Than Warren Buffett
There is no doubt that Warren Buffett is one of…
Stock Ideas
Buy
68
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
61
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 40x
Alerts
Buy
60
RGC alert for May 10
Regencell Bioscience Holdings [RGC] is up 79.25% over the past day.
Buy
97
NGVC alert for May 10
Natural Grocers by Vitamin Cottage [NGVC] is up 30.26% over the past day.
Sell
38
ONTO alert for May 10
Onto Innovation [ONTO] is down 30.17% over the past day.
